Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Wake Forest University Health Sciences
AstraZeneca
Sotio Biotech Inc.
National Cancer Institute (NCI)